Phytopharm shares dive after disappointing Parkinson's drug study results

Shares in development stage pharmaceutical group Phytopharm fell sharply on Monday after the company reported that a drug it has been developing to treat Parkinson's disease did not produce any improvements in patients' symptoms during a study.

Shares in development stage pharmaceutical group Phytopharm fell sharply on Monday after the company reported that a drug it has been developing to treat Parkinson's disease did not produce any improvements in patients' symptoms during a study.

The company, which has been developing a treatment trademarked 'Cogane', published the results of a study of the drug on unmedicated patients with early stage Parkinson's disease.

Subscribe to MoneyWeek

Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Get 6 issues free
https://cdn.mos.cms.futurecdn.net/flexiimages/mw70aro6gl1676370748.jpg

Sign up to Money Morning

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Sign up
MoneyWeek

MoneyWeek is written by a team of experienced and award-winning journalists, plus expert columnists. As well as daily digital news and features, MoneyWeek also publishes a weekly magazine, covering investing and personal finance. From share tips, pensions, gold to practical investment tips - we provide a round-up to help you make money and keep it.